KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Income Statement
NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 423.24M | 270.26M | 220.18M | 38.54M | 0.00 | |||
| Cost Of Goods | 60.91M | 33.41M | 22.89M | 9.10M | N/A | |||
| Gross Profit | 362.33M | 236.85M | 197.28M | 29.44M | N/A | |||
| Operating Expenses | 407.94M | 262.05M | 187.51M | 186.08M | 157.36M | |||
| Research and Development | 111.62M | 76.10M | 65.49M | 99.30M | 112.04M | |||
| Selling, General, and Administrative Expenses | 168.01M | 129.43M | 97.95M | 85.95M | 45.32M | |||
| Operating Income | -45.62M | -25.20M | 9.77M | -156.64M | -157.36M | |||
| Interest Income/Expense | 9.46M | 8.54M | 1.25M | 97.00K | 1.13M | |||
| Income Before Taxes | -36.15M | -16.65M | 11.03M | -156.54M | -156.23M | |||
| Income Tax | 7.04M | -30.74M | -172.34M | 1.39M | 5.15M | |||
| Net Income | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | |||
| EBITDA | -43.92M | -22.86M | 12.17M | -154.28M | -154.95M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 | |||
| Non GAAP EPS | -0.61 | 0.18 | 2.59 | -2.30 | -2.58 | |||
| Statistics | ||||||||
| Gross Profit Margin | 85.61% | 87.64% | 89.60% | 76.39% | N/A | |||
| Profit Margin | -10.21% | 5.21% | 83.28% | -409.72% | N/A | |||
| Operating Profit Margin | -10.78% | -9.32% | 4.44% | -406.38% | N/A | |||
All data in USD